Institute of Hematology & Blood Diseases Hospital, China clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19
What changed in the last 30 days
28 trials changed in the last 30 days: 6 stopped, 16 with notable changes, 6 with minor changes only.
- Notable: ZBR · Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM Primary completion pushed from Mar 15, 2025 to Nov 15, 2026
- Stopped: Optimal Timing of Hepatitis B Vaccination After Transplants Withdrawn before enrolling
- Stopped: Using the Composite Immune Risk Score to Assess and Modulate the Patient's Post-transplant Immune Reconstitution Trial terminated
- Notable: IASO206 · Relapsed/Refractory Multiple Myeloma Enrollment increased: 12 → 18 participants
- Notable: Impact of Closed PBSC Collection With Reduced Gas-Phase Oxygen Exposure on Graft Quality and Early Engraftment in Allo-HSCT Start date pushed from Oct 1, 2026 to Nov 1, 2026
-
Minor: 3 trials marked Unknown by the registry's verification sweep Changed
- Minor: 2023-D-ES · Anti-CD38 Antibody Treating Evans Syndrome Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
- Minor: Use of Blinatumomab · NGS-MRD Relapsed B-ALL After Autologous/Allogeneic Transplantation Changed Registry marked status Unknown (sponsor has not verified the record since Jun 2024); last known: Not Yet Recruiting
- Minor: ITP · TPO-RA in Primary Immune Thrombocytopenia (ITP) in Patients Older Than 14 Years Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
- Notable: YTS109 Cell Injection · Relapsed/Refractory Autoimmune Hemolytic Anemia Primary completion pushed from Dec 30, 2025 to Jun 30, 2027
- Notable: DARA-AA-001 · Daratumumab · Refractory Aplastic Anemia Recruitment opened
- Minor: Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia Trial completed
- Stopped: KL003 Cell Injection in Severe Sickle Cell Disease Trial status changed: Not Yet Recruiting → Suspended
- Notable: IASO206 · Relapsed/Refractory Autoimmune Hemolytic Anemia Primary completion pushed from Dec 31, 2026 to Dec 31, 2027
- Stopped: hypo-CASH · Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy · Severe Aplastic Anemia Trial terminated
- Stopped: CD7 CAR T Cells (RD13-02) · Relapsed/Refractory Severe Aplastic Anemia Recruitment suspended
- Stopped: Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients Trial terminated
- Notable: VRD-based Regimen Combined With CART-ASCT-CART2 Treatment · Primary Plasma Cell Leukemia Primary endpoint(s) modified
- Notable: Growth and Development-related Outcomes · Transfusion-dependent Beta-thalassemia After Gene Therapy Primary completion moved earlier from Dec 31, 2028 to Dec 31, 2027
- Notable: CAR T-cell Therapy Targeting CD19 and BCMA · AIHA Who Have Failed ≥3 Lines of Therapy Primary completion pushed from Feb 5, 2026 to Jan 12, 2027
- Notable: Brain Function and Psychological Changes Related to Cell Therapy for Autoimmune Hemolytic Anemia Primary completion pushed from Dec 31, 2026 to Dec 31, 2027
- Notable: KL003 Cell Injection · Transfusion-dependent β-thalassemia Primary completion pushed from Aug 20, 2025 to Aug 20, 2027
- Notable: F182112 in Relapsed/Refractory Autoimmune Hemolytic Anemia Recruitment opened
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New trial filings, last 30 days
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-11-17 | NCT07943039 Safety and Efficacy of pALG in Conditioning Regimen for HLA-Matched Sibling HSCT in… | Not Yet Recruiting | |
| 2026-11-13 | NCT07936162 Immune Reconstitution and Clinical Prognosis Following Umbilical Cord Blood… | Recruiting | |
| 2026-11-12 | NCT07930793 Aplastic Anemia Life-Course Cohort Study | Recruiting | |
| 2026-11-12 | NCT07932054 Immune Reconstitution Characteristics and Influencing Factors Following Umbilical Cord… | Recruiting | |
| 2026-11-06 | NCT07921550 Venetoclax Plus Inotuzumab Reduced-Intensity Induction Sequentially Followed by… | Not Yet Recruiting | |
| 2026-11-06 | NCT07921615 QLS4131 Plus Isa-V-CHOP in Newly Diagnosed, HIV-Negative PBL: A Single-Center… | Phase 2 | Not Yet Recruiting |
| 2026-11-05 | NCT07919119 Risk Stratification Value of Deep NGS-MRD Detection in Acute Myeloid Leukemia Patients… | Not Yet Recruiting | |
| 2026-10-29 | NCT07903623 QLS4131 Plus Isatuximab in Newly Diagnosed Primary Plasma Cell Leukemia | Phase 2 | Recruiting |
| 2026-10-29 | NCT07903636 QLS4131 for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease | Phase 2 | Not Yet Recruiting |
| 2026-10-29 | NCT07903649 A Randomized, Controlled Clinical Study on the Efficacy and Safety of Umbilical Cord… | Phase 2 | Completed |
Active trials by phase
| Early Phase 1 | 18 | |
| Phase 1 | 34 | |
| Phase 1/2 | 26 | |
| Phase 2 | 104 | |
| Phase 2/3 | 5 | |
| Phase 3 | 11 | |
| Phase 4 | 5 |
Not charted: 74 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Disease areas by active trials, top 10 of 19
Leukemia (92) · Acute Myeloid Leukemia (AML) (43) · Multiple Myeloma (39) · Acute Lymphoblastic Leukemia (ALL) (33) · Non-Hodgkin Lymphoma (31) · Hemophilia (14) · DLBCL (8) · Myelodysplastic Syndromes (MDS) (6) · Chronic Lymphocytic Leukemia (CLL) (4) · Follicular Lymphoma (4)
Get alerts when Institute of Hematology & Blood Diseases Hospital, China's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.